Peculiarities of treating patients with insomnia and anxiety comorbidity: in search for a safe alternative to benzodiazepines


  • O.O. Kopchak PHEI “Kyiv Medical University”, Kyiv, Ukraine



insomnia, anxiety, diagnosis, treatment


The article presents the definition and modern diagnostic criteria for insomnia, highlights the aspects of common pathogenetic mechanisms of insomnia and anxiety development. Approaches to the treatment of insomnia are described in detail. The place of Valeo-Dorm Duo, a preparation of phyto-flavonoid chrysin with anxiolytic effect and melatonin, in the treatment of patients with anxiety and insomnia is considered.


Benca R.M., Cirelli C., Tononi G. Basic science of sleep. In: Sadock B.J., Sadock V.A., Ruiz P. eds. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 9th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins. 2009. P. 362­375.

Vgontzas A.N., Bixler E.O., Papanicolaou D.A. et al. Rapid eye movement sleep correlates with the overall activities of the hy-po­thalamic­pituitary­adrenal axis and sympathetic system in healthy humans. J. Clin. Endocrinol. Metab. 1997. Vol. 82. P. 3278­3280. doi: 10.1210/jcem.82.10.4307.

Morgan P.T., Edward F. Pace­Schott E.F., Mason G.F., Forseliu E. Cortical GABA levels in primary insomnia. Sleep. 2012. Vol. 35(6). P. 807­14. doi: 10.5665/sleep.1880.

Siegel J.M. The neurotransmitters of sleep. J. Clin. Psychiatry. 2004. Vol. 65(16). P. 4­7.

Neubauer D.N., Pandi­Perumal S.R., Spence D.W., Buttoo K., Monti J.M. Pharmacotherapy of Insomnia. Journal of Central Nervous Sys-tem Disease. 2018. Vol. 10. P. 1­7. doi: 10.1177/1179573518770672.

American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Med-icine. 2014.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, Virginia: American Psychiatric Association. 2013. Available at: http://dsm.psychiatryonline/

Yang C.M., Lin S.C., Cheng C.P. Transient insomnia versus chronic insomnia: a comparison study of sleep­related psychologi-cal/behavioral characteristics. J. Clin. Psychol. 2013. Vol. 69. P. 1094­1107. doi: 10.1002/jclp.22000.

Vgontzas A.N., Bixler E.O., Lin H.M. et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalam-ic­pituitary­adrenal axis: clinical implications. J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 3787­3794. doi: 10.1210/jcem.86.8.7778.

Pinto Jr. L.R., Alves R.C., Fontenelle J. et al. New guidelines for diagnosis and treatment of insomnia. Arq. Neuropsiquiatr. 2010. Vol. 68. P. 666­675.­282X2010000400038.

Roth T., Roehrs T., Pies R. Insomnia: pathophysiology and implications for treatment. Sleep Med. Rev. 2007. Vol. 11. P. 71­79. doi: 10.1016/j.smrv.2006.06.002.

Puzino К., Frye S.S., LaGrotte C. A. et al. Am I (hyper)aroused or anxious? Clinical significance of pre-sleep somatic arousal in young adults. J. Sleep Res. 2019. e12829.

Arroll B., Fernando A., Falloon K. et al. Prevalence of causes of insomnia in primary care: a cross­sectional study. Br. J. Gen. Pract. 2012. Vol. 62. e99­e103. doi: 10.3399/bjgp12X625157.

Sateia M.J., Buysse D.J., Krystal A.D., Neubauer D.N., Heald J.L. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J. Clin. Sleep Med. 2017. Vol. 13(2). P. 307­349. doi: 10.5664/jcsm.6470.

Ellis J.G., Perlis M.L., Neale L.F., Espie C.A., Bastien C.H. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. J. Psychiatr. Res. 2012. Vol. 46(10). P. 1278­1285. doi: 10.1016/j.jpsychires.2012.07.001.

Richardson G.S. Human physiological models of insomnia. Sleep Med. Rev. 2007. Vol. 8(suppl. 4). S9­S14. doi: 10.1016/S1389­9457(08)70003­0.

Buysse D.J., Angst J., Gamma A. et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep. 2008. Vol. 31. P. 473­480. doi: 10.1093/sleep/31.4.473.

Gregory A.M., Caspi A., Eley T.C. et al. Prospective longitudinal associations between persistent sleep problems in childhood and anxie-ty and depression disorders in adulthood. J. Abnorm. Child. Psychol. 2005. Vol. 33. P. 157­163. doi: 10.1007/s10802­005­1824­0.

American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd ed. Westches-ter, Illinois: American Academy of Sleep Medicine. 2005.

Centers for Disease Control and Prevention. Key sleep disor­ders. July 1, 2013. Available at: Accessed August 1. 2015.

Riemann D., Baglioni C., Bassetti C., Bjorvatn B. et al. European guideline for the diagnosis and treatment of insomnia. J. Sleep Res. 2017. Vol. 26(6). P. 675­700. doi: 10.1111/jsr.12594.

DiBonaventura M., Richard L., Kumar M. et al. The Association between Insomnia and Insomnia Treatment Side Effects on Health Sta-tus, Work Productivity, and Healthcare Resource Use. PLoS One. 2015. Vol. 10(10). e0137117. doi: 10.1371/journal.pone.0137117.

Spira A.P., Kaufmann C.N., Kasper J.D. et al. Association between insomnia symptoms and functional status in U.S. older adults. J. Ger-ontol. B. Psychol Sci Soc. Sci. 2014. Vol. 69(1). S35­S41. doi: 10.1093/geronb/gbu116.

Baglioni C., Battagliese G., Feige B. et al. Insomnia as a predictor ofdepression: a meta­analytic evaluation of longitudinal epidemiological studies. J. Affect Disord. 2011. Vol. 135(1­3). P. 10­19.

Hagg S.A., Toren K., Lindberg E. Role of sleep disturbances in occupational accidents among women. Scand. J. Work Environ. Health. 2015. Vol. 41(4). P. 368­376. doi: 10.5271/sjweh.3495.

Laugsand L.E., Strand L.B., Vatten L.J., Janszky I., Bjorngaard J.H. Insomnia symptoms and risk for unintentional fatal injuries­the HUNT Study. Sleep. 2014. Vol. 37(11). P. 1777­1786. doi: 10.5665/sleep.4170.

Fernandez­Mendoza J., Vgontzas A.N., Liao D. et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension. 2012. Vol. 60(4). P. 929­935. doi: 10.1161/HYPERTENSIONAHA.112.193268.

Bathgate C.J., Edinger J.D., Wyatt J.K., Krystal A.D. Objective but not subjective short sleep duration associated with increased risk for hypertension in individuals with insomnia. Sleep. 2016. Vol. 39(5). P. 1037­1045. doi: 10.5665/sleep.5748.

Walters K., Rait G., Griffin M., Buszewicz M., Nazareth I. Recent Trends in the Incidence of Anxiety Diagnoses and Symptoms in Primary Care. PLoS One. 2012. Vol. 7(8). e41670. doi: 10.1371/journal.pone.0041670.

Li X., Zhu L., Su Y., Fang S. Short­term efficacy and tole­rability of venlafaxine extended release in adults with generalized anxiety disor-der without depression: A meta­analysis. PLoS One. 2017. Vol. 12(10). e0185865. doi: 10.1371/journal.pone.0185865.

Cuijpers P., Sijbrandij M., Koole S., Huibers M. et al. Psychological treatment of generalized anxiety disorder: a meta­analysis. Clin. Psy-chol. Rev. 2014. Vol. 34(2). P. 130­40. doi: 10.1016/j.cpr.2014.01.002.

Pae C.U., Wang S.M., Han C. et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta­analysis. J. Psychiatr. Res. 2015. Vol. 64. P. 88­98. doi: 10.1016/j.jpsychires.2015.02.017.

Ohayona M.M., Roth Th. Place of chronic insomnia in the course of depressive and anxiety disorders. Journal of Psychiatric Research. 2003. Vol. 37. P. 9­15.

Shi Y., Dong J.W., Zhao J.H., Tang L.N., Zhang J.J. Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence. Current Neuropharmacology. 2014. Vol. 12. P. 289­302. doi: 10.2174/1570159X11666131227001243.

Nuss Ph. Anxiety disorders and GABA neurotransmission: a disturbance of modulation Neuropsychiatric Disease and Treatment. 2015. Vol. 11. P. 165­175. doi: 10.2147/NDT.S58841.

Schutte­Rodin S., Broch L., Buysse D., Dorsey C., Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J. Clin. Sleep Med. 2008. Vol. 4. P. 487­504.

Golombek D.A., Pandi­Perumal S.R., Brown G.M., Cardinali D.P. Some implications of melatonin use in chronopharmacology of insomnia. Eur. J. Pharmacol. 2015. Vol. 762. P. 42­48. doi:10.1016/j.ejphar.2015.05.032.

Lie J.D., Tu K.N., Shen D.D., Wong B.M. Pharmacological Treatment of Insomnia. P&T. 2015. Vol. 40(11). P. 759­771. PMC 4634348.

Monti J.M. The neurotransmitters of sleep and wake, a physio­logical reviews series. Sleep Med. Rev. 2013. Vol. 17. P. 313­315. doi: 10.1016/j.smrv.2013.02.004.

Saper C.B., Chou T.C., Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001. Vol. 24. P. 726­731. doi: S0166223600020026.

Levenson J.C., Kay D.B., Buysse D.J. The Pathophysiology of Insomnia Chest. 2015. Vol. 147(4). P. 1179­1192. doi: 10.1378/chest.14­1617.

Wasowski C., Marder M. Flavonoids as GABAA receptor ligands: the whole story? J. Exp. Pharmacol. 2012. Vol. 4. P. 9­24. doi: 10.2147/JEP.S23105.

Bateson A.N. Further potential of the GABA receptor in the treatment of insomnia. Sleep Med. 2006. Vol. 7. S3­S9. doi: 10.1016/j.sleep.2006.03.001.

Longo L.P., Johnson B. Addiction: part I. Benzodiazepines — side effects, abuse risk, and alternatives. Am. Fam. Physician. 2000. Vol. 61. P. 2121­2128. PMID: 10779253.

American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2012. Vol. 60. P. 616­631. doi: 10.1111/j.1532­5415.2012.03923.

Appel K., Rose T. Fiebich B. et al. Modulation of the γ­aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother. Res. 2011. Vol. 25(6). P. 838­43. doi: 10.1002/ptr.3352.

Elsas S.M., Rossi D.J., Raber J. et al. Passiflora incarnata L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, va­rying with extraction method The role of melatonin in mood disorders. Phyto-medicine. 2010. Vol. 17(12). P. 940­949. doi: 10.1016/j.phymed.2010.03.002.

Movafegh A., Alizadeh R., Hajimohamadi F., Esfehani F., Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulato-ry surgery patients: a double­blind, placebo­controlled study. Anesth. Analg. 2008. Vol. 106(6). P. 1728­32. doi: 10.1213/ane.0b013e318172c3f9.

Rodríguez­Landa J.F., Hernández­López F., Cueto­Escobedo J. et al. Chrysin (5,7­dihydroxyflavone) exerts anxiolytic­like effects through GABAA receptors in a surgical menopause model in rats. Biomed Pharmacother. 2019. Vol. 109. P. 2387­2395. doi: 10.1016/j.biopha.2018.11.111.

Rezzoug M., Bakchieche B. Gherib A. et al. Chemical composition and bioactivity of essential oils and Ethanolic extracts of Ocimum basilicum L. and Thymus algeriennsis Boiss Boiss. & Reut. from the Algerian Saharan Atlas. BMC Complementary and Alternative Medcine. 2019. Vol. 19. P. 146­019­2556­y.



To practicing Neurologist